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Introduction: Renal replacement therapy is the treatment of end-stage chronic kidney disease
and  can be performed through dialysis catheters, arteriovenous ﬁstulas/grafts, and periton-
eal  dialysis. Patients are usually immunocompromised and exposed to invasive procedures,
leading  to high rates of infection and increased mortality.
Objectives: To compare the prevalence of infection and related deaths, as well as the sensitiv-
ity  proﬁle of the putative bacteria in patients treated with peritoneal dialysis, arteriovenous
ﬁstula  hemodialysis and catheter hemodialysis.
Methods: This is case–control study. Six hundred forty-four patients undergoing renal
replacement  therapy were selected. Patients were divided into three groups according to
the modality of dialysis treatment: peritoneal dialysis (126 patients), arteriovenous ﬁstula
hemodialysis  (326 patients), and catheter hemodialysis (192 patients).
Results:  One hundred sixteen patients (18.01%) developed infection. There was a higher
incidence  of infection in the peritoneal dialysis group (44 patients; 34.92%; OR: 3.32; CI
95%  = 2.13–5.17; p = 0.0001). In the catheter hemodialysis group, 48 patients (25%) had infec-
tion (OR: 1.88; CI 95%: 1.24–2.85; p = 0.0035). In the arteriovenous ﬁstula hemodialysis group,
24  patients (7.36%) developed infection (OR: 0.19; CI 95%: 0.12–0.31; p = 0.0001). Five patients
(4.31%)  died due to infection (four in the peritoneal dialysis group and one in the catheter
hemodialysis  group). There were no deaths due to infection in the arteriovenous ﬁstula
hemodialysis  group.Conclusions:  Peritoneal dialysis is the treatment with greater risk of infection and mortality,
hemfollowed  by catheter in  arteriovenous ﬁstula he
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Introduction
Chronic kidney disease (CKD) has high prevalence and
incidence worldwide, particularly in Brazil.1 Although the
National  Kidney Foundation (NKF)2 in 2002 has proposed
staging CKD in order to slow the advance toward the func-
tional  failure of the kidneys, difﬁculties such as lack of early
diagnosis,  inadequate treatment in the early stages, delayed
specialized monitoring, and the complexity of the disease
lead  many  people to need renal replacement therapy (RRT).1–3
RRT can be implemented through hemodialysis (HD), perit-
oneal  dialysis (PD), and renal transplantation. Each treatment
has  its own characteristics, advantages, disadvantages, and
complications.4 Peritoneal dialysis allows the patient home
treatment  decreasing outpatient visits. Hemodialysis can be
performed through a central catheter (CH) inserted in the
internal  jugular or subclavian vein or through an arteriove-
nous  ﬁstula (AVF) preferably in the upper limbs whose optimal
functionality delay varies from one to three months.5,6 Noso-
comial  infection is one of the most serious complications and
the  second cause of death in dialysis patients.7 The risk factors
that  predispose to nosocomial infection in RRT may  be inﬂu-
enced  by patient characteristics, site of dialysis access, and
disorders  of the skin and mucous membranes8; and comor-
bidities  such as diabetes mellitus, anemia, cardiovascular
disease, immunosuppression, and metabolic imbalances.4,5
Peritonitis is the most frequent infection in patients under-
going  PD, and septicemia is the most frequent complication
among patients on HD, especially when conducted through
a  central venous catheter. The kind of vascular access for
HD  has signiﬁcant inﬂuence on patient survival. Catheters
are  associated with substantially greater risk of septicemia,
hospitalization, and mortality compared to AVF.9 There are
few  studies in Brazil evaluating infection rates, the preva-
lent  microorganisms and the susceptibility proﬁle of bacterial
infections  associated with RRT. These data may be useful for
empirical  anti-infective therapy in these patients, as well as
to  better evaluate the choice of dialysis treatment aiming at
preventing infections. The objective of the present study was
to  compare the prevalence of infection and related deaths, as
well as the sensitivity proﬁle of the putative bacteria in RRT
treated  patients.
Methods
This is a case–control study. The study sample consisted of
644  patients treated in the RRT outpatient center at Santa
Casa  de Misericordia de Ponta Grossa Hospital during a 29-
month  period. Patients on RRT who developed nosocomial
infection (116 patients) were  considered as cases. Patients who
did not develop infection (528 patients) were considered as
controls.  Nosocomial infections were  considered when the
Commission  of Hospital Infection Control (CHIC) identiﬁed
the  case as such, based on clinical features, complementary
blood tests, and culture results of biological material. Uncon-
ﬁrmed  cases of infection by the CHIC were  excluded. The
patients  were  divided into three groups according to the type
of  dialysis treatment: PD (116 patients), CH (192 patients), and 1 4;1  8(3):281–286
arteriovenous ﬁstula hemodialysis (AVH) (326 patients). The
study  was approved by the local ethics committee.
Statistical  analysis
To compare categorical variables, two-tailed Fisher’s exact test
with Bonferroni correction for multiple comparisons was used.
To  evaluate the effect size Odds Ratio (OR) was  calculated
with 95% conﬁdence interval (CI) and its transformation in
probability  (p). The samples were  properly tested for nor-
mality  by Anderson–Darling test. The presence of outliers was
checked  by the Grubbs test. The statistical power of the sample
was  computed in each comparison. Results are presented as
mean ± standard deviation (SD). Analyses, including descrip-
tive  statistics, were performed using EPI INFO program.  p < 0.05
was considered statistically signiﬁcant.
Results
Of the 644 patients who underwent dialysis during the
study  period, 116 (18.1%) developed some infection (63 male;
57.22  ± 12.76 years). One hundred ﬁfty-six infections were
reported.  Seventy-one (45.51%) infections (56.14 ± 11.22 years)
were  in patients on PD, 60 (38.46%) infections (59.82 ± 13.33
years)  in patients on CH, and 25 (16.2%) infections in patients
on  AVH (53.8 ± 14.7 years) (Table 1).
Comparison  between  groups
Of the 126 patients undergoing PD, 44 (34.92%) had at least
one  infection during the study period, which was  signiﬁcantly
higher  than that in the other two groups (OR: 3.32; CI 95%:
2.13–5.17; p = 0.0001). CH also showed up as a risk factor for
the  development of infection with 48 (25%) of the 192 infected
patients  (OR: 1.8824; CI 95%: 1.24–2.85; p = 0.0035). The lowest
incidence of infection was observed in AVH group: 24 (7.36%) of
326  patients (OR: 0.19; CI 95%: 0.12–0.35; p = 0.0001). For all com-
parisons  made, the statistical power was greater than 99%,
with  a consequent error – beta less than 1% (Table 2).
Individual  comparison  between  groups
Comparing the groups individually, AVH turned out to be the
safest  method with less infections, resulting in lower inci-
dence  of morbidity when compared with CH (OR: 0.23; CI
95%:  0.14–0.40; p = 0.0001) and PD (OR: 0.14; CI 95%: 0.08–0.25;
p  = 0.0001). There was no statistically signiﬁcant difference
between the incidence of infections in the PD group and the
CH  group (OR: 0.62; CI 95%: 0.38–1.01; p = 0.0593). The statisti-
cal  power to detect these differences was 100% in both cases,
therefore  no beta error (Table 3).Deaths
Of patients infected (116), ﬁve died due to infection, with an
overall  mortality rate of 4.31%. There were  four deaths (9.09%)
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Table 1 – Patient characteristics by age and sex.
PD CH AVH Total
n % n % n % n %
Sex
Male 21 47.72 29  60.41 13 54.16 63 54.31
Female 23 52.27 19 39.58 11 45.83 53 45.68
Total 44 37.93 48 41.37 24 20.68 116 100
Age 56.14 ± 11.22 59.82 ± 13.33 53.8 ± 14.70 57.22 ± 12.76 p = 0.84
PD, peritoneal dialysis; CH, central catheter hemodialysis; AVH, arteriovenous ﬁstula hemodialysis.
Table 2 – Rate of infection in patients on renal replacement therapy according to the type of dialysis.
Type of dialysis Patients with
infection
n  (%)
Patients
without
infection
n  (%)
OR (CI 95%)b Pc pa Statistical
power (%)
AVF 24 (7.36) 302 (92.63) 0.19 (0.12–0.31) 6.12 0.00011 100
Catheter 48 (25) 144 (75) 1.88 (1.24–2.85) 1.53 0.00352 99.2
Peritoneal 44 (34.92) 82 (65.07) 3.32 (2.13–5.17) 1.30 0.00013 99.8
Total 116 528 – – – –
a Fisher’s exact test with correction for Bonferroni multiple comparisons. Considering a signiﬁcant p < 0.017.
b Odds Ratio (OR) with Conﬁdence Interval (CI) of 95%.
c Probability (P). 1 hemodialysis by arteriovenous ﬁstula (AVH) versus hemodialysis by catheter (CH) + peritoneal dialysis (PD). 2 CH versus
AVH + DP. 3 DP versus AVH + CH. RRT = renal replace therapy. AVF = arteriovenous ﬁstula.
Table 3 – Comparison of the infection frequency in the different groups of dialysis.
Groups Patients with
infection
n  (%)
Patients
without
infection
n (%)
OR (CI 95%)b Pc pa Statistical
power (%)
AVF 24 (7.36) 302 (92.63) 0.23 (0.14–0.40) 3.19 0.00011 100
Catheter 48 (25) 144 (75) 0.62 (0.38–1.01) 0.60 0.05932 100
Peritoneal 44 (34.92) 82 (65.07) 0.14 (0.08–0.25) 5.75 0.00013 100
Total 116 528 – – – –
a Fisher’s exact test with Bonferroni correction for multiple comparisons. Considering signiﬁcant p < 0,017.
b Odds Ratio (OR) with Conﬁdence Interval (CI) of 95%.
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ites  of  infection  and  bacterial  etiology
icrobiological tests were  carried out in 151 (96.78%) patients,
ith  infections turning out positive in 126 (80.76%). CH group
as  the group with the highest positivity rate (93.33%; 56/58
ultures),  followed by the PD group (81.28%; 59/71 cultures) and
he  AVH group (52%; 13/22 cultures). The biological samples
sed  for culture were  peritoneal ﬂuid in 46.47% of infec-
ions  of PD group, blood culture in 72.41% of infections of
H  group and 40.9% of infections of AVH group. Other sam-
les  used for culture were  catheter secretion, dialysate ﬂuid,
ardiac  valve secretion, sputum, and urine (Table 4). The
ost  common infection in the PD group was  peritonitis inmodialysis by catheter (CH). 2 hemodialysis by catheter (CH) versus
la (AVH). AVF = arteriovenous ﬁstula.
55 (77.46%) patients. In CH group, bloodstream infection was
the  most frequent infection occurring in 44 (73.33%) patients.
Vascular  access was the commonest site of infection in AVH
group  occurring in 12 (48%) patients (Table 5). Staphylococcus
aureus was  the most commonly recovered bacteria present
in  44 (32.59%) cases (24 in PD group, 16 in CH group, and 4
in  AVH group). Coagulase-negative Staphylococcus spp. (SNPC)
was  recovered from 47 (34.81%) cases (13 in PD group, 29 in CH
group,  and 5 in AVH  group). Escherichia coli was  isolated in 18
(13.33%)  cases (10 in PD group, 6 in CH group, and 2 in AVH
group).  Other less frequent bacteria are shown in Table 6.
Sensitivity  proﬁle  of  etiologic  agentsThe sensitivity proﬁles of the main isolated bacteria are shown
in  Table 7. Among the most important ﬁndings, 5 (11.4%)
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Table 4 – Microbiological culture results from patients on different types of dialysis.
Culture PD CH AVH Total
n % n % n % n
Positive 57 81.28 56 93.33 13 52 126
Negative 14  19.71 2  3.33 9  36 25
Not done 0  0 2 3.33 3 12 5
Total 71 45.51 60 38.46 25 16.02 156
PD, peritoneal dialysis; CH, central catheter hemodialysis; AVH, arteriovenous ﬁstula hemodialysis.
Table 5 – Site of infection in patients on different types of dialysis.
PD CH AVH Total
n % n % n % n %
Site
Peritonitis 55 77.46 0 0 0 0 55 35.25
Blood stream (BS) 3 4.22 44 73.33 4 16 51 32.69
Related to vascular access/catheter 12 16.90 14 23.33 12 48 38 24.35
Urinary tract infection (UTI) 0 0 2 3.33 2 8 4 2.5
Respiratory tract infection 0 0 0 0 4 16 4 2.5
Endocarditis 0 0 0 0 3 12 3 1.92
Peritonitis + BS + UTI 1 1.40 0 0 0 0 1 0.64
Total 71 45.51 60 38.46 25 16.02 156 100
PD, peritoneal dialysis; CH, central catheter hemodialysis; AVH, arteriovenous ﬁstula hemodialysis.
Table 6 – Etiology of infections from patients on different types of dialysis.
Bacterium PD CH AVH Total
n % n % n % n
Staphylococcus aureus 24 40.67 16 25.39 4 30.76 44
SNPC 13 22.03 29 46.03 5 38.46 47
Enterococcus faecalis 1 1.69 1 1.58 1 7.69 3
Streptococcus sp. 1 1.69 0 0 0 0 1
Escherichia coli 10 16.94 6 9.52 2 15.38 18
Klebsiella pneumoniae 3 5.08 2 3.17 0 0 5
Serratia spp. 2 3.38 3 4.76 0 0 5
Enterobacter spp. 0 0 2 3.17 1 7.69 3
Proteus vulgaris 0 0 1 1.58 0 0 1
Pseudomonas aeruginosa 3  5.08 3 4.76 0 0 6
Acinetobacter baumannii 2 3.38 0 0 0 0 2
Total 59 43.70 63 46.66 13 9.62 135
Polymicrobial infection 2 3.50 6 10.71 0 0 8
Monomicrobial infection 55 96.49 50 89.28 13 100 118
iovenPD, peritoneal dialysis; CH, central catheter hemodialysis; AVH, arter
methicillin-resistant S. aureus (MRSA) isolates, all observed in
PD group, and 7 (15.2%) methicillin-resistant SNPC infections
(6  in CH group) stand out. There was  no reported resistance to
neither vancomycin nor rifampicin. One (5.5%) E. coli isolate
from  PD group was  extended-spectrum -lactamase producer
(ESBL)  and multidrug resistant to antimicrobials. Multidrug
resistant Klebsiella pneumoniae was  recovered from two isolates
(40%),  one from PD group and another from CH group. Iso-
lates  of Serratia spp. (5) were susceptible to most antimicrobials
tested.  Resistant Pseudomonas aeruginosa was  observed in only
one isolate (16.7%) from CH group. Carbapenem resistance
was  not detected. The remaining isolates were susceptible to
most antibiotics tested. Overall, multidrug resistant bacterialous ﬁstula hemodialysis.
infections were recovered from 16 (10.26%) patients: 9 (56.25%)
from  CH group and 7 (43.75%) from PD group, representing
14.28% and 11.86% infections, respectively, with no statisti-
cal  difference (OR: 1.23; CI 95%: 0.42–3.5; p = 0.7914; statistical
power  of 100%). No multidrug resistant isolate was  recovered
from  AVH group.
DiscussionAs previously reported, PD patients had higher rate of infec-
tion  compared to CH and AVH patients.9–12 Likewise, a high
mortality rate (9.9%) of infected patients was  observed in PD
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Table 7 – Sensitivity proﬁle of the main isolated bacteria.
Antimicrobial S. aureus SNPC E. coli K. pneumoniae P. aeroginosa
n s % n s % n s % n s % n s %
Azithromycin 44 32 72.72 46 19 41.30
Ampicillin  (Amp) 18 3 16.66 5 0 0
Amp/Sulbactam 18 11 61.11 5 2 40
Cefazolin 18 12 66.66 5 2 40
Cefalotin 44 39 88.63 46 38 82.60 18 12 66.66 5 2 40
Ceftazidime 18 14 77.77 5 3 60 6 5 83.33
SMT + TMT 44 40 90.90 46 31 67.39
Gentamicin  44 39 88.63 46 31 67.39 18 12 66.66 5 3 60 6 5 83.33
Ciproﬂoxacin 44 39 88.63 46 34 73.91 18 10 55.55 5 4 80 6 5 83.33
Amikacin 18 16 88.88 5 3 60 6 5 83.33
Ceftriaxone 18 17 94.44 5 4 80
Meropenem 18 18 100 5 5 100 6 6 100
Penicillin 44 8 18.18 46 5 10.86
Oxacillin  44 39 88.63 46 39 84.78
Vancomycin  44 44 100 46 46 100
Cefepime 16 16 100 5 4 80 6 5 83.33
Aztreonam 16 16 100 5 4 80 6 5 83.33
Erithromycin 44 32 7272 46 33 71.73
Clindamycin 44  37 84.09 46 32 69.56
Chloramphenicol 44 40 90.90 46 44 95.65
PIP  + TZB 16 16 100 5 5 100 6 5 83.33
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Tobramycin 
roup when compared to CH patients (2.08%). Johnson et al.13
eported a mortality rate of 7.6% and 4.2%, respectively, also
howing  an increased risk of death in infected PD patients.
ower  rates (3.5%) of mortality in PD were reported by Bar-
etti  et al.14 Peritonitis is the main limitation of PD and is
ery  frequent.11,13–15 In CH group, bloodstream infection is
he  most common site of infection. In the present study,
loodstream infection was  presented in 73.33% of patients
n  CH group, compared to 16% in AVH group and 4.22% in
D  group. These results are similar to several studies repor-
ing  50–80% of bloodstream infections16 mostly related to the
se  of catheters.11,12,16 Couto et al.15 describe aseptic peri-
onitis, an entity found in about 10% of cases, where there
s  no identiﬁed etiological agent. In the present study 19.71%
f  negative cultures were found in PD group with clinically
iagnosed peritonitis. Furthermore, culture was  made in all
ases  with no possibility of underreporting. The most fre-
uent  infectious agents isolated were  Gram positive bacteria
esponsible for 70.36% of all infections. Similar values are
ound  in the study by Silva et al.6 with 60% of cases, in Aslan
t  al.11 with 62%, and in Couto et al.15 with 67% of cases. Other
tudies  show that the proportion of Gram positive and Gram
egative  bacteria is similar.17,18 S. aureus and SNPC were the
ost  frequent pathogens isolated, as in other studies.14,15,19–21
ethicillin resistant SNPC was  found in 15.2% of infections, a
ower rate of resistance than the 58.4% and 100% reported by
arretti et al.14 and Britta et al.,20 respectively. The incidence
f  MRSA in the present study was  11.4% compared to rates
f  14.3%,14 22%,22 23%,20 and 43.4%17 found in other studies.
ram negative organisms were  responsible for 23.69% of all
nfections  in the present study. E. coli was  the most frequent
ith  13.33%. Seventeen of 18 cultures (94.45%) were sensi-
ive  to ceftriaxone, whereas 66.7% and 55.6% were sensitive
o  ciproﬂoxacin and cefalotin. Britta et al.20 reported a study6 6 100
in which E. coli had 100% resistance to these antibiotics. An
isolate  of E. coli was  ESBL producer (5.55%), multidrug resis-
tant,  and sensitive to meropenem. As in the study by Sader
et  al.23 no resistance to this antibiotic was  found in the present
study.  For K. pneumoniae 80% was sensitive to ceftriaxone and
60%  to ceftazidime. Nogueira et al.24 showed 53.3% and 80%
sensitivity, respectively, and Almeida et al.25 reported 34% sen-
sitivity  for both antibiotics. Serratia, Enterobacter, and Proteus
were  also isolated (Table 6). Non-fermentative bacilli were  iso-
lated in eight (5.92%) cultures, P. aeruginosa in six (4.44%) of
which  only one (16.7%) was  multidrug resistant, and Acineto-
bacter  baumannii was  recovered in two cultures. Britta et al.20
showed multidrug resistance in 50% of cases. Polymicrobial
infections were observed in 3.5% of cases of PD group, a rate
much  lower than the 30%,15 10.7%,18 and 9.09%25 reported by
other  studies. In CH group polymicrobial infections were  more
frequently  isolated (10.71%). The lower rate of resistance of the
isolates  in the present study translates into reduced morbid-
ity  and hospital costs.26 This ﬁnding could be attributed to the
antimicrobial control policy implemented by the CHIC, which
is  based on quarterly updates of clinical sensitivity of local
microbiota and prescription supervision of electronic medical
records.
Conclusions
The present study provides evidence that the type of vascular
access  in RRT is an important predisposing factor for infection
which,  in turn, increases comorbidity and hospital costs. The
AVF  for hemodialysis is the safest access for RRT. These results
emphasize  the need for early referral program for patients
with  CKD regarding the indication and maturation of the dial-
ysis  method. This policy decreases morbidity, mortality, and
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hospital costs. More  studies are needed, especially those that
are  prospective and adequately powered.
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